Absorption of water-soluble compounds with different molecular weights and [Asu1.7]-eel calcitonin from various mucosal administration sites

Yamamoto, Akira; Iseki, Tomoya; Ochi-Sugiyama, Michiko; Okada, Naoki; Fujita, Takuya; Muranishi, Shozo

doi:10.1016/s0168-3659(01)00454-0

Cited by 62 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…37 The decrement of plasma glucose and calcium level (D%) after the pulmonary administration of insulin and calcitonin with or without PAMAM dendrimers was calculated using the following equation, as reported previously 38,39 :…”

Section: Methodsmentioning

confidence: 99%

Polyamidoamine Dendrimers Can Improve the Pulmonary Absorption of Insulin and Calcitonin in Rats

Dong

Hamid

Gao

et al. 2011

Journal of Pharmaceutical Sciences

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Polyamidoamine Dendrimers Can Improve the Pulmonary Absorption of Insulin and Calcitonin in Rats

Dong

Hamid

Gao

et al. 2011

Journal of Pharmaceutical Sciences

Self Cite

View full text Add to dashboard Cite

“…Moreover, pulmonary absorption is greater for small molecular compounds (MW <1000), and the absorption of high molecular weight substances including N-siRNA, from the lung into the systemic circulation may be limited. 19) Therefore, after deep deposition in the lung following inhalation using nebulizers, N-siRNA may remain in the lung fluid.…”

Section: Effects Of N-sirna Concentrations and Nebulizer Types On Mmamentioning

confidence: 99%

Inhalation Properties and Stability of Nebulized Naked siRNA Solution for Pulmonary Therapy

2016

View full text Add to dashboard Cite

The use of naked unmodified small interfering RNA (N-siRNA) without vector has previously been investigated as a pulmonary therapy. However, little is known regarding stabilities and aerodynamic particle sizes of N-siRNA-containing droplets; nebulizers have not yet been optimized for N-siRNA solutions. Thus, in this study, we investigated the feasibility of inhaled N-siRNA solutions for pulmonary therapy using nebulization. Various nebulizers and N-siRNA concentrations were assessed in terms of siRNA integrity after nebulization, and inhalation properties including aerodynamic particle size were examined. In comparison with ultrasonic-, air-jet-, and vibrating-mesh nebulizers, N-siRNA integrity was not affected by nebulization. Thus, in further experiments, performances of N-siRNA aerosols with different nebulizers and N-siRNA concentrations were evaluated and screened using an aerodynamic particle sizer (APS) which employed the time-of-flight principle or a cascade impactor. Mean mass aerodynamic diameters of N-siRNA-containing droplets from vibrating-mesh nebulizers tended to decrease with increasing N-siRNA concentrations, reflecting the influence of N-siRNA solutions on surface tension, as indicated by contact angles. These data indicate the utility of APS instruments for investigating the nebulized characteristics of expensive drugs including siRNAs and may facilitate the development of N-siRNA inhalation formulations.Key words small interfering RNA (siRNA); vibrating-mesh nebulizer; aerodynamic particle size; surface tension; contact angle Small interfering RNA (siRNA) has a great therapeutic potential as a tool for the post-transcriptional silencing of target gene expression. 1) Recently, the field of siRNA delivery has rapidly progressed, and the local pulmonary delivery of siRNA has been investigated for various lung diseases. 2,3)Inhalation is the most popular noninvasive method for delivering therapeutic siRNA agents to the lungs 4); local siRNA inhalation therapy reduced virus titers in the lung and attenuated local pulmonary chemokine production after acute lung injury and infection.5,6) However, naked (unmodified) siRNA (N-siRNA) is susceptible to nuclease degradation; siRNA delivery systems facilitating gene silencing efficiency, including those using cationic materials, can have cytotoxic effects. N-siRNA has been delivered with some success to the lung, although systemic delivery of N-siRNA generally fails to produce significant gene silencing effects.3,7) N-siRNA lacks delivery vectors that produce toxicity and inflammation; thus, N-siRNA formulation for pulmonary delivery offers advantages for safety and simplicity. However, few developments of N-siRNA formulations have been reported. Direct pulmonary N-siRNA delivery has been achieved in humans following the inhalation of aerosols generated by inhalers or nebulizers. Three types of inhalation devices are currently available for pulmonary drug delivery, including metered dose inhalers, dry powder inhalers, and nebulizers. Liquid nebulization e...

show abstract

“…Indeed, the pulmonary absorption of these drugs was significantly improved by coadministration with various adjuvants such as absorption enhancers and protease inhibitors. 1,[6][7][8][9][10][11][12] However, these absorption enhancers with high effectiveness may sometimes cause severe membrane damage to the rat lung tissues.…”

Section: Introductionmentioning

confidence: 99%

Chitosan Oligomers as Potential and Safe Absorption Enhancers for Improving the Pulmonary Absorption of Interferon-α in Rats

Yamada

Odomi

Okada

et al. 2005

Journal of Pharmaceutical Sciences

Self Cite

View full text Add to dashboard Cite

Absorption of water-soluble compounds with different molecular weights and [Asu1.7]-eel calcitonin from various mucosal administration sites

Cited by 62 publications

References 38 publications

Polyamidoamine Dendrimers Can Improve the Pulmonary Absorption of Insulin and Calcitonin in Rats

Polyamidoamine Dendrimers Can Improve the Pulmonary Absorption of Insulin and Calcitonin in Rats

Inhalation Properties and Stability of Nebulized Naked siRNA Solution for Pulmonary Therapy

Chitosan Oligomers as Potential and Safe Absorption Enhancers for Improving the Pulmonary Absorption of Interferon-α in Rats

Contact Info

Product

Resources

About